Literature DB >> 3532893

Calcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism.

L M Resnick, F B Müller, J H Laragh.   

Abstract

Circulating levels of the calcium-regulating hormones, calcitonin, calcitriol, and parathyroid hormone, were analyzed in relation to plasma renin activity in 10 persons with normal blood pressure and in 51 persons with essential hypertension. Calcitriol (p less than 0.008) and parathyroid hormone (p less than 0.01) levels were elevated in hypertensives with low renin activity, whereas calcitonin levels were higher in patients with high renin activity (p less than 0.008), compared with normotensive controls and other hypertensive patients. Continuous relationships were observed between calcitriol levels and plasma renin activity in all patients (r = -0.65, p less than 0.001) and between parathyroid hormone levels and urinary sodium excretion in hypertensive patients with low renin activity (r = -0.63, p less than 0.01). Together, these results support a linkage between calcium metabolism and renin-sodium factors in essential hypertension. Calcium-regulating hormones and the renin-aldosterone system may coordinately mediate the blood pressure effects of differing dietary calcium and sodium intakes at the cellular level by altering cellular handling of monovalent and divalent ions.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3532893     DOI: 10.7326/0003-4819-105-5-649

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  95 in total

Review 1.  The relationship between vitamin D and the renin-angiotensin system in the pathophysiology of hypertension, kidney disease, and diabetes.

Authors:  Anand Vaidya; Jonathan S Williams
Journal:  Metabolism       Date:  2011-11-09       Impact factor: 8.694

2.  New clinical trials with vitamin D and analogs in renal disease.

Authors:  Rajiv Kumar
Journal:  Kidney Int       Date:  2011-08-10       Impact factor: 10.612

Review 3.  Should hypertensive patients take vitamin D?

Authors:  Gregoire Wuerzner; Michel Burnier; Bernard Waeber
Journal:  Curr Hypertens Rep       Date:  2012-08       Impact factor: 5.369

4.  Serum 25-hydroxyvitamin-D and nonalcoholic fatty liver disease: Does race/ethnicity matter? Findings from the MESA cohort.

Authors:  Samar R El Khoudary; Saad Samargandy; Irfan Zeb; Temitope Foster; Ian H de Boer; Dong Li; Matthew J Budoff
Journal:  Nutr Metab Cardiovasc Dis       Date:  2019-09-10       Impact factor: 4.222

5.  1,25-dihydroxyvitamin D3 modulates growth of vascular smooth muscle cells.

Authors:  T Mitsuhashi; R C Morris; H E Ives
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

6.  Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans.

Authors:  John P Forman; Jonathan S Williams; Naomi D L Fisher
Journal:  Hypertension       Date:  2010-03-29       Impact factor: 10.190

7.  Association of vitamin D status and blood pressure response after renal denervation.

Authors:  Janine Pöss; Felix Mahfoud; Christian Ukena; Murray David Esler; Markus Schlaich; Dagmara Hering; Bodo Cremers; Ulrich Laufs; Michael Böhm
Journal:  Clin Res Cardiol       Date:  2013-10-31       Impact factor: 5.460

8.  Vitamin D status is not related to development of atrial fibrillation in the community.

Authors:  Michiel Rienstra; Susan Cheng; Martin G Larson; Elizabeth L McCabe; Sarah L Booth; Paul F Jacques; Steven A Lubitz; Xiaoyan Yin; Daniel Levy; Jared W Magnani; Patrick T Ellinor; Emelia J Benjamin; Thomas J Wang
Journal:  Am Heart J       Date:  2011-08-11       Impact factor: 4.749

9.  1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system.

Authors:  Yan Chun Li; Juan Kong; Minjie Wei; Zhou-Feng Chen; Shu Q Liu; Li-Ping Cao
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

Review 10.  The noncalciotropic actions of vitamin D: recent clinical developments.

Authors:  Naim M Maalouf
Journal:  Curr Opin Nephrol Hypertens       Date:  2008-07       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.